Lupin receives approval from USFDA for Bromfenac Ophthalmic
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Subscribe To Our Newsletter & Stay Updated